



Addressing significant unmet medical needs
in central nervous system diseases
with a unique portfolio of product candidates

July 2018

Forward-Looking Statement Safe-Harbor

This presentation contains forward-looking statements about Minerva Neurosciences which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this presentation, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to: the benefits, efficacy and safety of our new formulations; the potential of the diagnosis and treatment of negative symptoms of schizophrenia and other diseases; whether studies performed on analogs or backups of our compounds are a good predictor of the clinical efficacy of our compounds; statements with respect to the timing and results of future clinical milestones with roluperidone (MIN-101), seltorexant (MIN-202) and MIN-117, including the Phase 3 trial of roluperidone, the Phase 2b trials of seltorexant and the Phase 2b trial of MIN-117; statements regarding our ability to successfully develop and commercialize our therapeutic products; our expectations regarding approval for our products by the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; estimates regarding the market potential for our products; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether any of our therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of roluperidone, seltorexant, MIN-117 and MIN-301, if any, will be consistent with the results of past clinical trials; whether roluperidone, seltorexant, MIN-117 and MIN-301 will be successfully marketed if approved; whether our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; the strength and enforceability of our intellectual property rights; competition from pharmaceutical and biotechnology companies; the development of and our ability to take advantage of the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018, as well as our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 12, 2018. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. Our audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we disclaim any obligation to update any forward-looking



Investment thesis

Differentiated assets

- ▶ Targeting significant unmet medical needs with innovative mechanisms of action

Lead product in pivotal Phase 3 trial

- ▶ Topline data read-out anticipated 1H 2019

Four Phase 2b studies ongoing

- ▶ Data read-outs anticipated in 2019

Well capitalized through multiple data read-outs in 2019

- ▶ \$121m cash balance at March 31, 2018


Experienced management team

- ▶ Decades of combined experience in clinical practice and CNS drug discovery & development

Pipeline of four innovative CNS compounds

Program	Primary Indications	MoA	Preclinical	Phase 1	Phase 2	Phase 3
Roluperidone MIN-101	Negative symptoms in schizophrenia	<ul style="list-style-type: none"> • 5-HT_{2A} antagonist • Sigma₂ antagonist 	<p>Phase 3 initiated Dec 2017 (MIN-101C07)</p>			
Seltorexant MIN-202	<p>Primary insomnia</p> <p>Major depressive disorder, as adjunctive therapy</p>	<ul style="list-style-type: none"> • Selective orexin2 antagonist 	<p>Phase 2b initiated Dec 2017 (ISM2005)</p> <p>Phase 2b initiated Sep 2017 (aMDD2001)</p> <p>Phase 2b initiated Dec 2017 (aMDD2002)</p>			
MIN-117	Major depressive disorder, as monotherapy	<ul style="list-style-type: none"> • 5-HT_{1A} • 5HT transporter • Alpha-1a, b • Dopamine transporter • 5-HT_{2A} 	<p>Phase 2b initiated Apr 2018 (MIN-117C03)</p>			
MIN-301	Parkinson's disease	<ul style="list-style-type: none"> • Neuregulin-1β1 activating ErbB4 	<p>Pre-clinical</p>			

Antipsychotics do not address negative symptoms and cognitive impairment associated with schizophrenia (and maybe worsen them?)



Source of chart and captions: Minerva Corporate Presentation. Slide 7. January 2018.

Source of statements: KOL Exploratories. January 9-10, 2018. Cello Health Advantage Inc.


Negative vs positive symptoms in schizophrenia

- Positive symptoms reflect an excess or distortion of normal functions
 - Delusions and hallucinations
 - Disorganized speech / thought
 - Grossly disorganized behaviour
 - Agitation
- Negative symptoms reflect a diminution or loss of normal functions
 - Affect blunted / flat affect
 - Alogia, or reduced speech and short answers
 - Avolition, or lack of motivation, sense of purpose, ability to follow through on plans
 - Anhedonia, or lack of pleasure and lack of interest
 - Asociality / social withdrawal

Negative symptoms account for a substantial portion of the morbidity associated with schizophrenia.” – Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5™)

Recent survey of psychiatrists ranks negative symptoms as the #1 unmet medical need for patients with schizophrenia

Key unmet needs for schizophrenia, 2017



*Higher scores denote greater importance assigned to the unmet need.
Source: Datamonitor Healthcare's proprietary schizophrenia survey, September 2017



Roluperidone clinical data


Peer-reviewed data publications

Davidson, M., et al., Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia, Am J Psychiatry, <http://www.medical-reprints.com/US-MN-AJP-Davidson>

Keefe, R., et al., Cognitive Effects of MIN-101 in Patients with Schizophrenia and Negative Symptoms: Results from a Randomized Controlled Trial, J Clin Psychiatry, <https://doi.org/10.4088/JCP.17m11753>

Kirkpatrick, B., et al., The brief negative symptom scale (BNSS): Sensitivity to treatment effects, Schizophr. Res. (2017), <https://doi.org/10.1016/j.schres.2017.11.031>


Roluperidone Phase 2b study design: monotherapy, double-blind, placebo-controlled in schizophrenic patients with negative symptoms






Specific effects on negative symptoms can only be determined in a placebo controlled study

Phase 2b study showed specific improvements in negative symptoms over 12 weeks and 36 weeks in both doses and stable positive symptoms


Core 12-week phase: Statistically significant improvements in the primary endpoint




36-week extension phase



Roluperidone: Paradigm change in schizophrenia treatment



≈60% of adult patients with schizophrenia who are treated have negative symptoms and are relapse free over 6 months



SZ=schizophrenia.

1. Wu et al. *Psychol Medicine*. 2006; 2. Millier et al. *J Market Acc Health Policy*. 2017;
3. Haro et al. *Schizophr Research*. 2015; 4. Nordstroem et al. *J Social Psychiatry*. 2017.



Roluperidone Phase 3


Designed to replicate successful Phase 2b

Design reviewed at end-of-Phase 2 meeting with FDA

Phase 3 initiated December 2017

Data read-out expected in first half of 2019

Roluperidone Phase 3 study design: monotherapy, double-blind, placebo-controlled in schizophrenic patients with negative symptoms



Phase 3 compared to Phase 2b: same patient population; same double-blind duration; same doses; PANSS NSFS primary endpoint; CGI-S and PSP secondary endpoints; 40-week extension allows 1 year safety coverage.

Phase 3 efficacy study: confirmatory study design guided by insights from Phase 2b and dialogue with FDA

Primary endpoint

- PANSS Negative Symptoms Factor Score (NSFS) according to Marder after 12 weeks' administration

Secondary endpoints

- Personal and Social Performance scale (PSP)
- Clinical Global Impression of Severity (CGI-S)
- 40 weeks (9 months) open-label extension
- 501 patients randomized 1:1:1 to 32 mg and 64 mg doses of MIN-101 vs placebo
 - Symptomatically stable patients for several months with moderate to severe negative symptoms (>20 PANSS NSFS) and stable positive symptoms
- If patients are on antipsychotic medication, switch to MIN-101 without long wash-out periods so as to mimic clinical practice
- Study carried out in US (approximately 30% of patients) and Europe

Powering assumptions

- 90% powered
- 40% drop-out rate



Seltorexant


MIN-202 / JNJ-42847922

A drug to treat insomnia and major depressive disorder by restoring physiological sleep

A co-development/co-commercialization program with:



Orexin system: Neurobiology targets circuits that mediate sleep and mood symptoms




Depressive Symptom	Orexinergic Domain
Depression/irritability	Emotion/arousal
Low self view/guilt	Emotion
Loss of interest and pleasure	Reward/motivation
Suicide/death ideation	Reward/motivation
Sleep disturbance	Sleep-wake
Agitation, restlessness	Arousal/energy balance


Name	MoA	PK/PD profile
Seltorexant	Selective orexin-2 Antagonist	<ul style="list-style-type: none"> Highly selective for orexin-2 (relative to orexin-1) Short Tmax (30 minutes) – produces rapid onset of effect Short half-life (2 hours) – minimizes daytime “hangover”

Seltorexant study in MDD with comorbid insomnia shows improvements in insomnia and depressive symptoms

Exploratory Phase 1a study in patients with major depressive disorder and insomnia (N = 20)



Minerva Neurosciences, internal data, study 42847922ED1002; disclosed Q1 2015.



Phase 1b study
Day 11, N = 47

HDRS₁₇ = 17-item Hamilton Depression Rating Scale; adjusted HDRS₁₇ = HDRS with the 3 items related to sleep subtracted; HDRS₆ = 6-item subscale encompassing the core symptoms of depression.

1. ACNP. 2016; ClinicalTrials.gov NCT02476058; 2. Diphenhydramine (Benadryl), included as a nocebo; 3. JNJ-7922.

Seltorexant Phase 2b program: 2 trials in MDD and 1 in insomnia ongoing, with data read-outs anticipated in 2019

- **First aMDD trial initiated Sep 2017** (clinicaltrials.gov: NCT03227224)
 - Double-blind, randomized, parallel-group, placebo-controlled adaptive dose-finding study
 - 4-week screening, 6-week double-blind treatment, and 2-week follow-up
 - ≈280 patients planned to be enrolled at >85 clinical sites in the US, Europe, Russia, and Japan
 - Safety and tolerability and dose-response and efficacy for up to 3 doses of seltorexant

- **Second aMDD trial initiated Dec 2017** (clinicaltrials.gov: NCT03321526)
 - Double-blind, randomized, flexible-dose parallel-group study
 - 4-week screening, 6-month double-blind treatment, and 2-week follow-up
 - ≈100 patients planned to be enrolled at ≈34 clinical sites in the US
 - Assess the efficacy of flexibly dosed seltorexant compared with flexibly dosed quetiapine as adjunctive therapy to baseline antidepressant therapy (either an SSRI or SNRI) in delaying time to all-cause discontinuation of study drug over a 6-month treatment period

- **Insomnia trial initiated Dec 2017** (clinicaltrials.gov: NCT03375203)
 - Double-blind, randomized, parallel-group, active- and placebo-controlled dose-finding study
 - Up to 61-day duration, including screening and follow-up
 - ≈360 patients planned to be enrolled at clinical sites in the US, Europe, and Japan
 - Assess the dose-response of 3 doses of seltorexant compared to placebo on sleep onset as measured by latency to persistent sleep (LPS) using polysomnography (PSG)
 - Assess the dose-response of these doses compared with placebo on wake after sleep onset (WASO) over the first 6 hours using PSG
 - Compare the effects of seltorexant on sleep and cognition to those effects of zolpidem




MIN-117


Addressing the unmet medical needs of patients with major depressive disorder and anxiety symptoms

The Phase 2a results show effect on primary endpoint in depression as well as noted effect on anxiety

MADRS Change from Baseline (MMRM LS Mean) by Treatment Arm (ITT Population)



HAM-A Change from Baseline (Observed data) by Treatment Arm (ITT Population)



Exploratory study for dose-finding, safety and efficacy – not statistically powered


Results

- Efficacy on depressive symptoms
- Onset evident as early as 2 weeks
- Efficacy on anxiety symptoms
- Both doses of MIN-117 are well tolerated, no sexual s/e, cognitive benefits


Assay sensitivity confirmed by positive separation of paroxetine from placebo

Sleep PSG shows intact REM latency resulting in preservation of sleep architecture and continuity of sleep, an important product differentiator

PSG REM Latency Change from Baseline (Observed Data) by Treatment Arm (ITT Population)



Ongoing Phase 2b study designed to evaluate MIN-117 in patients with moderate to severe MDD



MIN-117 Phase 2b study objectives

Primary:

- To evaluate the efficacy of 5.0 mg or 2.5 mg of MIN-117 compared with placebo in reducing the symptoms of MDD as measured by the change from baseline in MADRS score over 6 weeks of treatment

Secondary:

- To evaluate the efficacy of 5.0 mg or 2.5 mg of MIN-117 compared with placebo in reducing symptoms of anxiety measured by
 - Hamilton Anxiety Scale (HAM-A)
 - Severity of illness and improvement using the Clinical Global Impression of Severity Scale (CGI-S) and the Clinical Global Impression of Improvement Scale (CGI-I)

Safety:


- To evaluate the safety of MIN-117 over 6 weeks of treatment (side effects observed with current MDD treatments include cognitive impairment, sexual dysfunction, sleep disorders and weight gain)



MIN-301

A protein drug with disease-modifying potential for the treatment of unmet medical needs in Parkinson's disease and other major CNS indications

Neuregulin-1 (NGR-1) has multiple roles in neuronal development offering potential for neuronal repair in several CNS indications; initial clinical focus will be Parkinson's disease



NRG-1 controls key neuronal development pathways

Image: Mei and Xiong, 2008.

Strong financial position to deliver on major milestones



≈\$121.1 million cash balance

*(cash, cash equivalents, and marketable securities)
at March 31, 2018*



≈38.7 million shares outstanding

*(≈45.5 M fully diluted)
at May 1, 2018*



Investment thesis

Differentiated assets

- ▶ Targeting significant unmet medical needs with innovative mechanisms of action

Lead product in pivotal Phase 3 trial

- ▶ Topline data read-out anticipated 1H 2019

Four Phase 2b studies ongoing

- ▶ Data read-outs anticipated in 2019

Well capitalized through multiple data read-outs in 2019

- ▶ \$121m cash balance at March 31, 2018

Experienced management team

- ▶ Decades of combined experience in clinical practice and CNS drug discovery & development